The antibody Lecanemab back-up was designed and generated to selectively target toxic protofibrils and oligomers, soluble aggregated forms of amyloid-beta.
BioArctic presented new data around Lecanemab back-up’s binding profile at the Alzheimer’s Association International Conference® 2019 (AAIC®) in Los Angeles, USA.
Please see BioArctic’s poster “Lecanemab back-up shows stronger binding to soluble aggregated amyloid-beta species than aducanumab” for more information.